10x Genomics, Inc.

NASDAQ:TXG

Medical - Healthcare Information Services

Healthcare
$57.07 +7.75%

+$2.49 today

Market cap
$6.93B
Beta
2.11
P/E (TTM)
-196.0
EPS (TTM)
-$0.18
52W Low $10.48High $35.65

Volume 2.10M

Average 3.06M

TXG Long-term Investments

Investments the company intends to hold for more than a year.

10x Genomics, Inc.NASDAQ: TXG

Long-term Investments · Q3 FY2026 · quarter ended Sep 2026

Long-term investments remains negative

Q3 FY2026 long-term investments was $0, compared with $201K a year earlier.

Context

  • Long-term investments amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Long-term investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term investments keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoSep 2025
$201K-100.0% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Long-term Investments vs competitors

How TXG compares with its peers on the latest reported figures

  • TXG's Sep 2026 long-term investments of $0 is the 7th highest of the 9 companies compared; the peer median is $69.72M.
  • Its year-over-year change of -100.0% is the 5th highest of 6, against a peer median of -3.7%.
  • Long-term investments amounts to 0.0% of total assets for TXG, versus a peer median of 3.5%.
TXG Competitors Peer median
Long-term Investments for TXG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BIOBio-Rad Laboratories, Inc.Jun 2026$5.72B +2.6%-11.6%55.8%
TECHBio-Techne CorporationSep 2026$245.61M -7.8%-0.3%9.3%
AAgilent Technologies, Inc.Jul 2026$130M -3.7%-12.0%0.9%
LABStandard BioTools Inc.Mar 2026$71.36M ——11.2%
TWSTTwist Bioscience CorporationSep 2026$68.09M +16.4%+189.3%6.1%
QGENQiagen N.V.Jun 2026$17M ——0.3%
TXG10x Genomics, Inc.Sep 2026$0 -100.0%—0.0%
ILMNIllumina, Inc.Jun 2026$0 -100.0%+17.0%0.0%
RVTYRevvity, Inc.Jul 2026$0 —-80.0%0.0%
Peer median (excluding TXG) $69.72M-3.7%-6.0%3.5%

Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents587.45M219.75M359.28M344.07M473.97M
Short-term Investments0210.24M29.41M49.34M49.44M
Net Receivables85.25M104.21M114.83M87.86M82.49M
Inventory59.97M81.63M73.71M83.11M56.34M
Other Current Assets1.03M19.21M18.79M20.02M22.21M
Total Current Assets747.59M635.04M596.02M584.39M684.45M
Property, Plant & Equipment (Net)230.41M359.21M344.93M309.94M287.16M
Goodwill4.51M4.51M4.51M4.51M4.51M
Intangible Assets25.4M22.86M16.62M15.67M62.33M
Long-term Investments7.6M0000
Tax Assets00000
Other Non-current Assets3.32M7.37M3.06M4.13M2.91M
Total Non-current Assets271.24M393.95M369.12M334.25M356.91M
Total Assets1.02B1.03B965.14M918.64M1.04B
Account Payables17.35M21.6M15.74M12.91M12.73M
Short-term Debt000010.99M
Tax Payables4.62M4.08M5.05M4.94M0
Deferred Revenue5.34M7.87M13.15M20.66M23.9M
Other Current Liabilities40.91M29.74M33.96M41.84M63.33M
Total Current Liabilities110.36M130.96M127.16M117.63M153.45M
Long-term Debt000073.38M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)03.17M8.81M12.51M10.5M
Other Non-current Liabilities14.05M2.98M4.28M5.03M(65.67M)
Total Non-current Liabilities90.9M92.28M96.94M90.87M91.59M
Total Liabilities201.26M223.24M224.1M208.5M245.04M
Common Stock2K2K2K2K2K
Retained Earnings(863.32M)(1.03B)(1.28B)(1.47B)(1.51B)
Accumulated OCI22K(4.34M)(429K)(493K)225K
Other Stockholders Equity00000
Minority Interest00000
Total Equity817.57M805.74M741.04M710.13M796.33M
Total Debt81.98M95.18M95.37M82.61M157.74M
Net Debt(505.47M)(124.57M)(263.91M)(261.45M)(316.23M)

10x Genomics, Inc.

NASDAQ:TXG

Intrinsic Alpha fair value

Locked

Current Price

$57.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.